F-group (family)
375.1.1.18 SIR2
Ligands and drugs
170
Member domains
153
with ligand contacts (≤ 4 Å)
90.0% of members
142
with DrugDomain annotations
83.5% of members
62
with a DrugBank compound
36.5% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 375.1.1.18 belongs to X-group 375 Rubredoxin-like, which binds 5.1 ligand superclasses per 20 proteins, narrower than 81% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB17057 | SR7 | SRT-1720 | 12 |
| DB00123 | LYS | Lysine | 6 |
| DB00149 | LEU | Leucine | 6 |
| DB14128 | NAD | Nadide | 6 |
| DB04381 | CRD | Crotonaldehyde | 5 |
| DB01118 | BBI | Amiodarone | 2 |
| DB03478 | OAD | 2'-O-Acetyl Adenosine-5-Diphosphoribose | 2 |
| DB08168 | MCM | Coumarin 120 | 2 |
| DB14475 | 2OP | L-Lactic acid | 2 |
| DB02701 | NCA | Nicotinamide | 1 |
| DB03553 | GUA | Glutaric Acid | 1 |
| DB03796 | PLM | Palmitic Acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 153 |
| OCZ | (1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1- carboxamide | 7 |
| LEU | LEUCINE | 6 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 6 |
| CRD | (2E)-BUT-2-ENAL | 4 |
| CNA | CARBA-NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 3 |
| 2OP | (2S)-2-HYDROXYPROPANOIC ACID | 2 |
| 4I5 | (6S)-2-chloro-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-6-carboxamide | 2 |
| 5I7 | (phenylmethyl) ~{N}-[(2~{S})-6-[[(2~{R},3~{a}~{R},5~{R},6~{R},6~{a}~{R})-5-[[[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl]oxymethyl]-6-oxidanyl-2-tridecyl-3~{a},5,6,6~{a}-tetrahydrofuro[2,3-d][1,3]oxathiol-2-yl]amino]-1-oxidanylidene-1-[2-(triethyl-$l^{4}-azanyl)ethylamino]hexan-2-yl]carbamate | 2 |
| 5IA | 2-{[(2S)-6-[(Z)-(1-{[(2R,3R,4R,5R)-5-({[(R)-{[(R)-{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl]oxy}(hydroxy)phosphoryl]oxy}methyl)-4-hydroxy-2-sulfanyloxolan-3-yl]oxy}tetradecylidene)amino]-2-{[(benzyloxy)carbonyl]amino}hexanoyl]amino}-N,N,N-triethylethan-1-aminium (non-preferred name) | 2 |
| CGK | 3-[(2R,3aR,5R,6R,6aR)-5-({[(S)-{[(S)-{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(hydroxy)phosphoryl]oxy}(hydroxy)phosphoryl]oxy}methyl)-2,6-dihydroxytetrahydrofuro[2,3-d][1,3]oxathiol-2-yl]propanoic acid | 2 |
| LYS | LYSINE | 2 |
| MGmetal | MAGNESIUM ION | 2 |
| OAD | 2'-O-ACETYL ADENOSINE-5-DIPHOSPHORIBOSE | 2 |
| XYQ | (2R,3R,4S,5R)-5-({[(R)-{[(R)-{[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHOXY}(HYDROXY)PHOSPHORYL]OXY}(HYDROXY)PHOSPHORYL]OXY}METHYL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL ACETATE | 2 |
| 0L1 | hexanedioic acid | 1 |
| 3OD | (2S,3S,4R,5S)-2-({[(S)-{[(S)-{[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHOXY}(HYDROXY)PHOSPHORYL]OXY}(HYDROXY)PHOSPHORYL]OXY}METHYL)-4,5-DIHYDROXYTETRAHYDROFURAN-3-YL ACETATE | 1 |
| A1JK1 | 2-(4,6-dimethylpyrimidin-2-yl)sulfanyl-~{N}-[5-[[3-(1~{H}-1,2,3-triazol-4-ylmethoxy)phenyl]methyl]-1,3-thiazol-2-yl]ethanamide | 1 |
| A1JK3 | 4-dodecyl-1-propyl-1,2,3-triazole | 1 |
| A1JK5 | 4-dodecyl-1-ethyl-1,2,3-triazole | 1 |